In a filing, Cardiff Oncology Inc revealed its Chief Financial Officer Levine James E. acquired Company’s shares for reported $14905.0 on Dec 17 ’24. In the deal valued at $5.42 per share,2,752 shares were bought. As a result of this transaction, Levine James E. now holds 65,316 shares worth roughly $0.22 million.
Then, Levine James E. bought 2,400 shares, generating $12,000 in total proceeds. Upon buying the shares at $5.00, the Chief Financial Officer now owns 67,716 shares.
Before that, Levine James E. bought 2,564 shares. Cardiff Oncology Inc shares valued at $9,820 were divested by the Chief Financial Officer at a price of $3.83 per share. As a result of the transaction, Levine James E. now holds 62,564 shares, worth roughly $0.21 million.
Craig Hallum initiated its Cardiff Oncology Inc [CRDF] rating to a Buy in a research note published on September 06, 2024; the price target was $8. A number of analysts have revised their coverage, including William Blair’s analysts, who began to cover the stock in early January with a ‘”an Outperform”‘ rating. Robert W. Baird began covering CRDF with “an Outperform” recommendation on December 08, 2021.
Price Performance Review of CRDF
On Friday, Cardiff Oncology Inc [NASDAQ:CRDF] saw its stock jump 2.10% to $3.41. Over the last five days, the stock has gained 18.40%. Cardiff Oncology Inc shares have fallen nearly -21.43% since the year began. Nevertheless, the stocks have risen 4.92% over the past one year. While a 52-week high of $5.64 was reached on 02/21/25, a 52-week low of $2.01 was recorded on 04/11/25. SMA at 50 days reached $2.95, while 200 days put it at $3.19.
Levels Of Support And Resistance For CRDF Stock
The 24-hour chart illustrates a support level at 3.27, which if violated will result in even more drops to 3.13. On the upside, there is a resistance level at 3.51. A further resistance level may holdings at 3.60. The Relative Strength Index (RSI) on the 14-day chart is 66.91, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.35, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 6.32%. Stochastics %K at 90.23% indicates the stock is a selling.
The most recent change occurred on October 22, 2020 when H.C. Wainwright began covering the stock and recommended ‘”a Buy”‘ rating along with a $27 price target.
